Mesothelioma Cancer Centers
Billings Clinic Cancer Center
Doctors Affiliated with this Treatment Facility
The Billings Clinic started with the expertise of two physicians in a general practice and eventually expanded into the largest practice in the region with over 250 physicians, physician assistants, and nurse practitioners in 35 health departments. The health system started under the general practice of Dr. Arthur J. Movius in 1911. Dr. J.H. Bridenbaugh joined Movius and brought experience in obstetrics and radiology to the practice. Over the next few decades, various physicians joined the facility due to an increase in the area population and a corresponding increase in the need for medical services. A decision was made in 1907 to begin developing a new hospital. The Billings Deaconness Hospital opened on June 30, 1927 with 58 beds, 12 doctors, and 16 nurses.
Several expansions took place over the next several years allowing for more physicians and nurses to join the facility, as well as for more advanced services and treatment options to be offered. In 1972, the hospital was able to pioneer the first successful open-heart surgery in Billings, Montana. The facility eventually merged with the Billings Clinic to become one health care organization known as The Deaconness Billings Clinic. The name changed to Billings Clinic in 2005, and within the next couple years a new emergency and trauma center, surgical center, and a new inpatient cancer care unit opened to the public. The center provided cancer care services on an inpatient and outpatients status.
The Billings Clinic Cancer Center is part of the non-profit health care organization, Billings Clinic, located in Billings, Montana. The hospital provides premium care to the citizens of Montana, Wyoming and the Western Dakotas. The Billings Clinic started with the expertise of two physicians in a general practice and eventually expanded into the largest practice in the region with over 250 physicians, physician assistants, and nurse practitioners in 35 health departments.
The Billings Clinic Cancer Center focuses on creating personalized care for all their patients through a multidisciplinary approach. They offer cancer risk assessments for those who are high risk for developing cancer, like those who have experienced past asbestos exposure. Once diagnosed, mesothelioma patients will experience collaborative care from oncologists, oncology nurses, genetic therapists, dietitians and more to ensure the best care possible. A preliminary plan is organized for each patient until the lung conference/tumor board can analyze all diagnostic findings and devise a recommended treatment plan. The physicians and support staff at the thoracic (lung) cancer program use a variety of diagnostic tools to detect cancer in patients including CT scans, bronchoscopy and thoracoscopy. These tools help physicians to determine a prognosis and recommended treatment plan.
The center features innovative technology to allow for comprehensive mesothelioma care. Specialists at the center in the Lung (Thoracic) Cancer Program are experienced in surgical procedures, chemotherapy and radiation therapy techniques to fit any patient’s needs. They also offer a variety of clinical trials, giving patients the opportunity to receive promising emerging therapies that could improve life expectancy, including cancer vaccines and gene therapy.
Billings Cancer Center also offers wellness and supportive programs to improve quality of life and lessen patient suffering. The offerings focus on integrative medicine, including nutrition plans, education and survivorship care programs.
- Targeted therapy
- Becker’s 100 Great Hospitals in America
- Truven 100 Top Hospitals
- Yale Global Health Leadership Institute Partnership
- QOPI Certified
- Commission on Cancer accreditation
Mesothelioma Clinical Trials at Billings Clinic Cancer Center
The following clinical trials are in progress or actively recruiting participants at Billings Clinic Cancer Center:
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma Last Updated: June 14, 2019 Status: Recruiting
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
Conditions: Biphasic Mesothelioma; Epithelioid Mesothelioma; Stage I Pleural Malignant Mesothelioma AJCC v7; Stage IA Pleural Malignant Mesothelioma AJCC v7; Stage IB Pleural Malignant Mesothelioma AJCC v7; Stage II Pleural Malignant Mesothelioma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7 Last Updated: June 13, 2019 Status: Recruiting
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Epithelioid Mesothelioma; Pleural Malignant Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatoid Mesothelioma Last Updated: January 16, 2019 Status: Active, not recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
Billings Clinic. Cancer Center.
Billings Clinic. Lung (Thoracic) Cancer Program.